Primary source Samsung Biologics (via PR Newswire): Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
On 27 August 2026, Samsung Biologics announced a rights offering expected to raise KRW 3 trillion. The headline says it funds the company's "next-phase expansion", but the allocation is lopsided: about KRW 2.71 trillion, roughly 90% of the total, goes to the planned acquisition of PolyPeptide Group, and about KRW 290 billion to the expansion of Bio Campus II in Songdo.
The acquisition
In July, Samsung Biologics announced an all-cash offer for PolyPeptide Group for CHF 1.46 billion (about KRW 2.71 trillion), to broaden its portfolio into peptide-based therapeutics beyond antibodies and ADCs. On 31 August it published the tender offer prospectus through its Swiss subsidiary Samsung Peptide AG: CHF 44.31 per share, a main offer period from 15 September to 12 October 2026, and a minimum acceptance threshold of 66⅔%. PolyPeptide's largest shareholder, Draupnir Holding, which holds about 55.65% of the shares, has undertaken to tender all of them. The prospectus makes the offer subject to regulatory approvals.
The capacity part
Samsung Biologics currently reports 845,000 L of total capacity: 785,000 L across Bio Campus I and II in Korea and 60,000 L from a site acquired in Rockville, Maryland. After completing Plant 5 at Bio Campus II in 2025, the company says it has been evaluating bringing Plants 6 to 8 online sequentially, which would take global capacity to 1,385,000 L by 2032. The release does not say how the KRW 290 billion is split, what Plants 6 to 8 would cost, or whether they have been approved.
The terms
- About 2,270,000 new shares at KRW 1,322,000 each, about 15% below the reference price.
- The raise equals about 4.90% of market capitalisation.
- 20% of the new shares go to the employee stock ownership association, as required by Korea's Capital Markets Act.
- Registration statement effective 30 September; subscription for existing shareholders on 9 and 10 November; new shares targeted for listing on 30 November.
What it means for a plant
Read the allocation, not the headline. This raise is mainly a modality move into peptides, bought rather than built; the new money for Bio Campus II is about a tenth of it, and the path to 1,385,000 L is still described as under evaluation. For anyone tracking biologics CDMO capacity, the firm number today is 845,000 L; the 2032 figure is a plan.
